Publications by authors named "Jen Barak-Levitt"

Background: Real-world data regarding the use of dupilumab in children with atopic dermatitis (AD) are limited.

Objectives: To evaluate the real-world efficacy of dupilumab in children with moderate-to-severe AD over an extended follow-up period.

Methods: This was a retrospective study of patients (≤ 18 years) with moderate-to-severe AD treated with dupilumab in four Israeli tertiary centres.

View Article and Find Full Text PDF

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease involving apocrine gland-bearing regions. There is an under-representation of non-Caucasians in epidemiologic studies of HS. The characteristics of HS in Israeli Arabs have not yet been studied.

View Article and Find Full Text PDF

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting patients of reproductive age. Although HS shares risk factors with male infertility, only 1 epidemiological study has evaluated this association. To further evaluate this potential association, findings on semen and hormonal analysis, testicular ultrasound, and the International Index of Erectile Function (IIEF-15) were compared between 28 men attending a tertiary HS clinic during the period April 2019 to April 2021, and 44 healthy controls, spouses of infertile women undergoing semen evaluation before in vitro fertilization.

View Article and Find Full Text PDF

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 20% of children. Methotrexate (MTX) is used off-label as a systemic treatment for AD patients unresponsive to topical therapies, but limited data exist regarding its safety and efficacy in children, especially in those < 4 years old. To further investigate MTX in younger patients, we screened the medical records of three referral centers between 2016 and 2022 and identified 28 infants and toddlers < 4 years old with AD treated with MTX.

View Article and Find Full Text PDF
Article Synopsis
  • Treatment for hidradenitis suppurativa (HS) varies widely and often falls short of patient expectations, prompting the study to develop an AI-based platform for evaluating treatments and patient outcomes.
  • The research involved analyzing data from 1,050 patients through online questionnaires, focusing on their clinical characteristics, comorbidities (like depression and anxiety), and treatment satisfaction to assess which treatments worked best.
  • Findings indicated that younger males experienced more severe HS symptoms, with different treatments rated based on severity stages, underscoring the importance of understanding comorbid conditions in managing HS effectively.
View Article and Find Full Text PDF

Background: Hidradenitis suppurativa (HS) is a chronic skin disease characterized by inflammatory nodules and abscesses. The pathogenic role of bacteria is not fully understood. As the diagnosis is usually delayed, patients are often treated with several lines of antibiotics in a nonstandardized fashion.

View Article and Find Full Text PDF